TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35224732

Group type: EXPERIMENTAL
Intervention: Cyclosporin with or without prednisone
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Cyclosporin with prednisone
Number of subjects: 560

Group type: COMPARATOR
Intervention: MMF compared with prednisone
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 560

Group type: COMPARATOR
Intervention: Other interventions (e.g., monoclonal antibodies, rituximab, dexamethasone)
Number of subjects: 560
Study: 35224730

Group type: COMPARATOR
Intervention: Antiplatelet agents
Number of subjects: 51959
Study: 35225085

Group type: EXPERIMENTAL
Intervention: EndoAnchors
Number of subjects: 54
Study: 35225821

Group type: EXPERIMENTAL
Intervention: Parent SMART + TAU
Number of subjects: 440

Group type: COMPARATOR
Intervention: Residential TAU only
Number of subjects: 440
Study: 35226112

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment for advanced HCC
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: High-risk subgroup (score = 3+)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Intermediate-risk subgroup (score = 2)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Low-risk subgroup (score = 0-1)
Number of subjects: 542
Study: 35226304

Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with fluvoxamine or fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with strong CYP2C19 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with strong CYP2C19/2C9 inducers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib co-administered with OAT3 inhibitors
Number of subjects: 0
Study: 35226559

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 0
Study: 35226732

Group type: EXPERIMENTAL
Intervention: Chair Stand Test (CST) cutoff of 14 seconds for ages 70-79
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Chair Stand Test (CST) cutoff of 16 seconds for ages 80+
Number of subjects: 1595
Study: 35226739

Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat) + rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAK-981 (subasumstat) + daratumumab
Number of subjects: 0
Study: 35226945

Group type: EXPERIMENTAL
Intervention: Motorized spiral enteroscopy (MSE)
Number of subjects: 170
Study: 35226999

Group type: EXPERIMENTAL
Intervention: Higher maternal stress levels (measured by PHQ-D)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Higher cortisol levels during pregnancy
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI
Number of subjects: 277
Study: 35227201

Group type: EXPERIMENTAL
Intervention: CT findings (Ground glass opacity, consolidation, pleural effusion)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: CT findings (Cluster with low prevalence of GGO and high prevalence of pleural effusion)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: CT findings (Pleural effusion)
Number of subjects: 380
Study: 35227313

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg/S-amlodipine 2.5 mg
Number of subjects: 316

Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 316
Study: 35228629

Group type: EXPERIMENTAL
Intervention: Increasing levels of PEEP
Number of subjects: 0
Study: 35229612

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulant (DOAC) use in patients with MHCs
Number of subjects: 67503

Group type: COMPARATOR
Intervention: Control group (patients without MHCs)
Number of subjects: 67503
Study: 35229652

Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy with increased frequency
Number of subjects: 0
Study: 35229827

Group type: EXPERIMENTAL
Intervention: Fractionated proton radiation therapy (FPRT) to a total dose of 50.4 to 54 Gy RBE over 28 to 30 fractions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FPRT
Number of subjects: 20
Study: 35230138

Group type: EXPERIMENTAL
Intervention: Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
Number of subjects: 0
Study: 35230142

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Number of subjects: 0
Study: 35230165

Group type: EXPERIMENTAL
Intervention: Prescription opioid use in women living with HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescription opioid use in women without HIV
Number of subjects: 0
Study: 35230183

Group type: EXPERIMENTAL
Intervention: TIC assessment of dynamic contrast-enhanced MRI scans
Number of subjects: 244

Group type: COMPARATOR
Intervention: Visual assessment of dynamic contrast-enhanced MRI scans
Number of subjects: 244
Study: 35230185

Group type: EXPERIMENTAL
Intervention: Cardiac MRI features including late gadolinium enhancement (LGE), T1 and T2 mapping, and extracellular volume fraction (ECV)
Number of subjects: 0
Study: 35230209

Group type: EXPERIMENTAL
Intervention: Reported executive functions (EFs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Objective executive functions (EFs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) assessment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive interventions targeting EFs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 35230243

Group type: EXPERIMENTAL
Intervention: PedAMINES app (mobile app)
Number of subjects: 278
Study: 35230254

Group type: EXPERIMENTAL
Intervention: Telemonitoring with antihypertensive treatment titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35230489

Group type: EXPERIMENTAL
Intervention: Intraoperative near-infrared fluorescence imaging (NIR-FI) with indocyanine green (ICG)
Number of subjects: 66
Study: 35230699

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 769

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone and prednisolone
Number of subjects: 769

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNIs) with reduced-dose prednisolone or without prednisolone
Number of subjects: 769

Group type: COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with reduced-dose prednisolone
Number of subjects: 769

Group type: COMPARATOR
Intervention: Levamisole and prednisolone
Number of subjects: 769
Study: 35230974

Group type: EXPERIMENTAL
Intervention: Targeting collagens that signal through LAIR-1 in combination with blockade of TGF-β and PD-L1
Number of subjects: 0
Study: 35230981

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 13
Study: 35231008

Group type: EXPERIMENTAL
Intervention: Topical estrogen
Number of subjects: 55
Study: 35231037

Group type: EXPERIMENTAL
Intervention: Patients with SMI
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Blood donors (control group)
Number of subjects: 1258
Study: 35232410

Group type: EXPERIMENTAL
Intervention: 90Y radioembolization
Number of subjects: 170
Study: 35232419

Group type: EXPERIMENTAL
Intervention: Interleukin-1 Receptor antagonist (IL-1Ra) measured in serum levels during 6 months follow-up.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Montgomery-Asberg Depression Rating Scale (MADRS) score, Alcohol Use Disorders Identification Test (AUDIT) score, Body Mass Index (BMI) assessments.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 242
Study: 35232680

Group type: EXPERIMENTAL
Intervention: Intravenous- or intravesical-administered immune checkpoint inhibitors
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pembrolizumab as monotherapy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor response
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Complete response rate
Number of subjects: 13
Study: 35232756

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 285
Study: 35234178

Group type: EXPERIMENTAL
Intervention: eLASV (estimated levator ani subtended volume)
Number of subjects: 51
Study: 35234654

Group type: EXPERIMENTAL
Intervention: eDOL mHealth app
Number of subjects: 105
Study: 35234658

Group type: EXPERIMENTAL
Intervention: Self-monitoring intervention using composite web-based multidimensional PA feedback with real-time daily feedback
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 51
Study: 35234659

Group type: EXPERIMENTAL
Intervention: Apple Watch Series 6
Number of subjects: 150

Group type: COMPARATOR
Intervention: Withings Move
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Apple Watch ECG and pulse oximeter features
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inpatient and outpatient healthcare utilisation
Number of subjects: 150
Study: 35234665

Group type: EXPERIMENTAL
Intervention: Adaptive closed-loop ECoG decoder for bimanual control of an exoskeleton
Number of subjects: 0
Study: 35234826

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous gentamicin (7.5 mg/kg daily for 14 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High-dose intravenous gentamicin (10 mg/kg daily for 24 days)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gentamicin treatment
Number of subjects: 5
Study: 35234887

Group type: EXPERIMENTAL
Intervention: DPP Group Lifestyle Balance (GLB) program delivered via face-to-face groups or DVD with weekly telephonic coach contact
Number of subjects: 99
Study: 35234975

Group type: EXPERIMENTAL
Intervention: Injured Achilles tendon
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Injured leg
Number of subjects: 37
Study: 35235003

Group type: EXPERIMENTAL
Intervention: Seizures (recurrent)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Seizures (single)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acidosis at seizure onset
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prior emergency operations
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epilepsy
Number of subjects: 200
Study: 35235061

Group type: EXPERIMENTAL
Intervention: DVP + Li
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DVP + QTP
Number of subjects: 75

Group type: COMPARATOR
Intervention: DVP + PBO
Number of subjects: 75
Study: 35235189

Group type: EXPERIMENTAL
Intervention: Bosutinib (first-line)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Bosutinib (second-line or later)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 1348
Study: 35235414

Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibition as Single Therapy
Number of subjects: 0
Study: 35235412

Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors plus endocrine therapy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 217
Study: 35235572

Group type: EXPERIMENTAL
Intervention: Benzodiazepines during the first trimester
Number of subjects: 3094227

Group type: EXPERIMENTAL
Intervention: Benzodiazepines <1 mg/day
Number of subjects: 3094227

Group type: EXPERIMENTAL
Intervention: Benzodiazepines >2.5 mg/day
Number of subjects: 3094227

Group type: EXPERIMENTAL
Intervention: Specific benzodiazepine agents
Number of subjects: 3094227

Group type: COMPARATOR
Intervention: Unexposed pregnancies
Number of subjects: 3094227
Study: 35235641

Group type: EXPERIMENTAL
Intervention: Indices of hyperinsulinemia derived from OGTT (area under the curve of insulin, peak insulin, fasting insulin, insulinogenic index, insulin at 30 min)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Low postprandial glucose <75 mg/dL
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Follow-up >4 years in a subsample of 104 participants
Number of subjects: 591
Study: 35235656

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Continuing current antiretroviral regimens (CAR)
Number of subjects: 493
Study: 35235725

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I measurements obtained 3 to 12 hours after surgery and on days 1, 2, and 3 after surgery.
Number of subjects: 13862
Study: 35235733

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35235940

Group type: EXPERIMENTAL
Intervention: SMART-3RP intervention
Number of subjects: 80
Study: 35236170

Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding
Number of subjects: 4470

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 4470
Study: 35236290

Group type: EXPERIMENTAL
Intervention: Healthy aging (HA)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Faster gait speed
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Faster performance in sit-to-stand test
Number of subjects: 2157
Study: 35236302

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) for 8 weeks (1500-3000 mg total daily dose)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Calcium carbonate (CC) for 8 weeks (1500-6500 mg total daily dose) followed by LC for 8 weeks (1500-3000 mg total daily dose)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) for up to 6 months (1500-3000 mg total daily dose)
Number of subjects: 166
Study: 35236331

Group type: COMPARATOR
Intervention: obinutuzumab (G)-CHOP
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: venetoclax+[G/R]-CHOP
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: BCL2/EZH2
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: MYD88/CD79B
Number of subjects: 509
Study: 35236342

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (VDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoke (CS) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D3 supplementation in COPD patients
Number of subjects: 0
Study: 35236373

Group type: EXPERIMENTAL
Intervention: Faith, Activity, and Nutrition (FAN) program intervention
Number of subjects: 92
Study: 35236375

Group type: EXPERIMENTAL
Intervention: Modified MaZiRenWan (MZRW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 35236419

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (confident, active, and happy youth)
Number of subjects: 20
Study: 35236510

Group type: EXPERIMENTAL
Intervention: SurgeCon quality improvement intervention
Number of subjects: 4
Study: 35236551

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation (UAS)
Number of subjects: 1963
Study: 35237053

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-7 days
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g every 24 h for 5-7 days
Number of subjects: 302
Study: 35237316

Group type: EXPERIMENTAL
Intervention: Antireflux mucosectomy
Number of subjects: 13
Study: 35237394

Group type: EXPERIMENTAL
Intervention: rFVIIIFc individualized prophylaxis
Number of subjects: 0
Study: 35237650

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 18
Study: 35237699

Group type: EXPERIMENTAL
Intervention: Transtibial root repair for medial and lateral posterior meniscal root tears
Number of subjects: 45

Group type: COMPARATOR
Intervention: Age ≥ 50 years
Number of subjects: 45

Group type: COMPARATOR
Intervention: Increased BMI, cartilage status, and meniscal extrusion
Number of subjects: 45
Study: 35237748

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 600 mg twice daily for five days
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 1092
Study: 35238436

Group type: EXPERIMENTAL
Intervention: First COVID-19 lockdown
Number of subjects: 239
Study: 35238467

Group type: EXPERIMENTAL
Intervention: Matched therapy recommended by the Molecular Tumor Board (MTB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Unmatched therapy
Number of subjects: 51
Study: 35238615

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture during chemotherapy infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35238785

Group type: EXPERIMENTAL
Intervention: OHI seeking
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: eHealth literacy among OHI seekers
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Higher eHealth literacy
Number of subjects: 76
Study: 35238793

Group type: EXPERIMENTAL
Intervention: mHealth-CR (mobile health cardiac rehabilitation)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 400
Study: 35238854

Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo kidney perfusion (NEVKP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anoxic hypothermic machine perfusion (Control)
Number of subjects: 39
Study: 35239084

Group type: EXPERIMENTAL
Intervention: Serum sTFR
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Serum RBP (Vitamin A)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Maternal iron status (ferritin and BIS) and anemia (hemoglobin)
Number of subjects: 1244
Study: 35239526

Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vessel-sealing device hemorrhoidectomy
Number of subjects: 80
Study: 35239543

Group type: EXPERIMENTAL
Intervention: Smartphone application (App) for pain assessment, used by 49% of parents (n = 772) at least once, for a duration of 10 days.
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Self-assessments of pain using a numerical rating scale (NRS)-11 for children older than 6 years.
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Pain medication, preoperative anxiety, postoperative nausea and vomiting, and parent satisfaction were analyzed.
Number of subjects: 1573
Study: 35239678

Group type: EXPERIMENTAL
Intervention: CNSD users (prolonged use ≥ 4 weeks)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cognitive function (measured by MMSE)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: CNSD use
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Cognistat
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Clock Drawing Test
Number of subjects: 246
Study: 35239692

Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 5
Study: 35239732

Group type: EXPERIMENTAL
Intervention: Ferric citrate, initial dose adjusted to maintain serum phosphorus at 3.5-5.5 mg/dL, mean dose of 3.35±1.49 g/day (range 1.5 to 6.0 g/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 202
Study: 35240856

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) imaging in patients with idiopathic DCM
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Ischemic-pattern LGE identified in patients with idiopathic DCM
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Coronary angiography results in patients with transmural or subendocardial LGE
Number of subjects: 1204
Study: 35241101

Group type: EXPERIMENTAL
Intervention: Dietary saturated fatty acids (SFAs)
Number of subjects: 409
Study: 35241119

Group type: COMPARATOR
Intervention: Conventional D-dimer threshold
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer threshold
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Wells-adjusted D-dimer threshold
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: YEARS-adjusted D-dimer threshold
Number of subjects: 368
Study: 35241141

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) at a dose of 2×10^6 cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs)
Number of subjects: 15
Study: 35241151

Group type: EXPERIMENTAL
Intervention: Human umbilical cord MSCs injected twice into the uterus
Number of subjects: 10
Study: 35241226

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose enoxaparin
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose enoxaparin
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban
Number of subjects: 3600
Study: 35241240

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (HT) in females aged ≥60 years (N = 2,153, 47.6%)
Number of subjects: 6873

Group type: COMPARATOR
Intervention: Females
Number of subjects: 6873
Study: 35241276

Group type: EXPERIMENTAL
Intervention: Low-profile RelayPro thoracic endograft
Number of subjects: 110
Study: 35241362

Group type: EXPERIMENTAL
Intervention: Residing in a state with restrictive HIV testing policies
Number of subjects: 612
Study: 35241475

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia awareness before diagnosis
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Awareness of symptoms of pre-eclampsia
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Involvement in decision making at diagnosis
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Increase in awareness of symptoms of pre-eclampsia over time
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Counselling about later-life health risks associated with pre-eclampsia
Number of subjects: 833
Study: 35241644

Group type: EXPERIMENTAL
Intervention: Branaplam, an orally available, brain penetrant small molecule
Number of subjects: 0
Study: 35241844

Group type: EXPERIMENTAL
Intervention: 50 µg booster injection of mRNA-1273
Number of subjects: 344
Study: 35241942

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (controlled-release 10 mg every 12 hours and immediate-release 5 mg every 4 hours as needed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral tramadol (controlled-release 100 mg every 8 hours and immediate-release 50 mg every 4 hours as needed)
Number of subjects: 60
Study: 35242224

Group type: EXPERIMENTAL
Intervention: Knowledge about behavioural risk factors of cancer
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Consumption of street food
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Consumption of packed-fried snacks
Number of subjects: 200
Study: 35242593

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with still images
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with 360° navigable images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0